A Phase 1 Study of REGN6569, a GITR Mab, in Combination with Cemiplimab in Patients (pts) with Advanced Solid Tumor Malignancies: Initial Dose-Escalation Results.
Journal of Clinical Oncology(2024)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined